*September 2019* by Dr. Mark Kris for Medscape
This is Mark Kris from Memorial Sloan Kettering. Just when we thought we were all set with EGFR, suddenly we have some disruptive information that challenges how we’re going to treat patients with EGFR-mutated cancers. At the American Society of Clinical Oncology (ASCO) annual meeting this year, three presentations fit this mold.
Adding to TKIs in Lung Cancer
The first one was a trial adding ramucirumab to erlotinib.[1] Patients who received ramucirumab with erlotinib had an improvement in progression-free survival (PFS) of about 7 months, a very substantial improvement.
The second abstract was perhaps an even more disruptive one, demonstrating that adding chemotherapy to gefitinib improves PFS by 8 months. Read the entire article.
